U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H24ClFN2O.CH4O3S
Molecular Weight 507.017
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LINRODOSTAT MESYLATE

SMILES

CS(O)(=O)=O.C[C@H]([C@H]1CC[C@H](CC1)C2=C3C=C(F)C=CC3=NC=C2)C(=O)NC4=CC=C(Cl)C=C4

InChI

InChIKey=LZNFBNWGSDOVIO-QEFLZESTSA-N
InChI=1S/C24H24ClFN2O.CH4O3S/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23;1-5(2,3)4/h6-17H,2-5H2,1H3,(H,28,29);1H3,(H,2,3,4)/t15-,16-,17+;/m1./s1

HIDE SMILES / InChI
Molecular Formula C24H24ClFN2O
Molecular Weight 410.912
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 1.1 nM [IC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
781 ng/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
701.9 ng/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
596 ng/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5922.3 ng × h/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6048.3 ng × h/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3380.8 ng × h/mL
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.9 h
CLINICAL TRIAL
https://classic.clinicaltrials.gov/ct2/show/results/NCT03792750
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: NIVOLUMAB
NIVOLUMAB
 LINRODOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:29:14 GMT 2025
Edited
by admin
on Mon Mar 31 22:29:14 GMT 2025
Record UNII
OS7OBU191R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-986205 MESYLATE
Preferred Name English
LINRODOSTAT MESYLATE
USAN  
Official Name English
CYCLOHEXANEACETAMIDE, N-(4-CHLOROPHENYL)-4-(6-FLUORO-4-QUINOLINYL)-.ALPHA.- METHYL-, (.ALPHA.R,1.ALPHA.,4.ALPHA.)-, METHANESULFONATE (1:1)
Systematic Name English
BMS-986205 METHANESULFONATE
Code English
LINRODOSTAT MESYLATE [USAN]
Common Name English
BMS-986205-04
Code English
Linrodostat mesylate [WHO-DD]
Common Name English
(2R)-N-(4-CHLOROPHENYL)-2-(CIS-4-(6-FLUOROQUINOLIN-4-YL)CYCLOHEXYL)PROPANAMIDEMETHANESULFONIC ACID (1:1)
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C174811
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
USAN
FG-198
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
EVMPD
SUB194070
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
SMS_ID
100000178342
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
CAS
2221034-29-1
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
FDA UNII
OS7OBU191R
Created by admin on Mon Mar 31 22:29:14 GMT 2025 , Edited by admin on Mon Mar 31 22:29:14 GMT 2025
PRIMARY
Related Record Type Details
Structure of LINRODOSTAT
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of LINRODOSTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966